Oculopharyngeal Muscular Dystrophy (OPMD) Market Players:
- Bristol-Myers Squibb
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- BioMarin
- Sarepta Therapeutics
- Benitec Biopharma Inc
- Bioblast Pharma
- PTC Therapeutics
- NS Pharma
- Nobel pharma Co. Ltd
- Santhera Pharmaceuticals
- Pfizer Inc.
- Fibrinogen
- GSK
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of oculopharyngeal muscular dystrophy is evaluated at USD 5.76 billion.
The global oculopharyngeal muscular dystrophy market size was worth around USD 5.11 billion in 2025 and is set to register a CAGR of more than 14.1%, exceeding USD 19.11 billion revenue by 2035.
By 2035, North America is projected to secure a 36% share in the oculopharyngeal muscular dystrophy (OPMD) market, supported by the rising incidence of OPMD cases across the region owing to the increasing frequency of the disorder.
Key players in the market include Bioblast Pharma, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd, Santhera Pharmaceuticals, Pfizer Inc., Marathon Pharmaceuticals, Fibrinogen, GSK.
